parallel randomized trial

S003436

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Children and adolescents with type 2 diabetesS003436

Design

Randomized: 150
Start year: 2023
Treatment: 24 weeks, follow-up 24 weeks
Countries: Pakistan (1 sites)
Sponsor: (non industry)
Eligibility: age 3 to 16 years; type 2 diabetes; prior lifestyle, alpha glucosidase inhibitor or metformin up to 750 mg/day

Conduct and analysis

Blinding: open label
Sequence generation: not reported
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population: completers
Missing data

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Metformin Metformin	none, prior oral drugs stopped at week 0; lifestyle: standard	75	75
A2	Liraglutide 0.9 mg injection once daily Liraglutide 0.9 mg daily	none, prior oral drugs stopped at week 0; lifestyle: standard	75	75

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Metformin A1	Liraglutide 0.9 mg injection once daily A2
age	mean (years)	11	10
age	sd (years)	3	4
diabetes duration	mean (years)	3.7	4.6
diabetes duration	sd (years)	3.5	3.9
female	n	25	30
hba1c	mean (percent)	8.1	7.9
hba1c	sd (percent)	0.6	0.8

Analyses this trial contributes to

Results

2 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

HbA1c change (2 lines; O01)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
24	A1	final	7.2 percent	0.8		75	not stated; completers; R0054221:Results
24	A2	final	7.1 percent	0.9		75	not stated; completers; R0054221:Results